Light it Red for Lymphoma

Since 2011, the Lymphoma Research Foundation has been a leader in raising awareness of lymphoma during National Blood Cancer Awareness Month in September. This year, more than 100 buildings and landmarks will Light it Red for Lymphoma on World Lymphoma Awareness Day and throughout September to bring hope to all of those affected by a lymphoma diagnosis.More >

2017 North American Educational Forum on Lymphoma

The North American Educational Forum on Lymphoma is a 2-½ day annual program providing critical information on treatment options, patient support issues, clinical trials and the latest advances in lymphoma research to people with lymphoma and their loved ones. More >

The FDA approves ibrutinib (IMBRUVICA®) for chronic graft versus host disease (cGVHD)

The FDA approves the use of ibrutinib (IMBRUVICA®) for chronic graft versus host disease (cGVHD). More >


Welcome to Focus on DLBCL

The FocusOnDLBCL website is designed to provide helpful information and resources to patients, caregivers, physicians, and others affected by diffuse large B-cell lymphoma (DLBCL). From understanding an initial diagnosis - including a patient's genetics and subtype - to learning about treatment options and clinical trials, this website provides the latest information from the world's leading experts in the field.

We invite you to browse the website to learn more about DLBCL.

Getting the Facts

Lymphoma is the most common blood cancer. The two main forms of lymphoma are Hodgkin lymphoma and non-Hodgkin lymphoma (NHL). Diffuse large B-cell lymphoma (DLBCL) accounts for about 30 percent of newly diagnosed cases of NHL in the United States and represents the most common subtype of lymphoma. Lymphoma occurs when cells of the immune system called lymphocytes, a type of white blood cell, grow and multiply uncontrollably. Malignant lymphocytes can travel to many parts of the body, including the lymph nodes, spleen, bone marrow, blood, or other organs, and form a mass called a tumor. The body has two main types of lymphocytes that can develop into lymphomas: B lymphocytes (B-cells) and T lymphocytes (T-cells).

Recent Research

Research into non-Hodgkin lymphoma and in particular DLBCL, the most common subtype of lymphoma, has led to significant advancements in the understanding of the disease. Research continues on multiple fronts to develop better treatments for patients. We hope you will find the information presented here useful in understanding your disease and discussing it with your healthcare team.

Patient Education Programs

The Lymphoma Research Foundation (LRF) is the nation’s largest nonprofit devoted to funding innovative research and serving the lymphoma community through a comprehensive series of education, advocacy and outreach efforts. LRF provides a comprehensive series of educational programs for people with lymphoma and their loved ones, including a number of in-person conferences on the local, regional, and national levels.

DLBCL YouTube Video